NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
Clinical Trials
13 trialsNCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05861830 2024-03-12
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Peking Union Medical College Hospital
Phase 3 Recruiting
NCT05753865 2023-03-03
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05439499 2022-07-06
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05438810 2022-07-05
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03538171 2021-07-09
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 3 Unknown
NCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02054338 2019-08-28
VICTORIA
Pierre Fabre Medicament
Phase 3 Terminated
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed